Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
Altaire instigates voluntary recall of sterile ophthalmic treatments, after concerns were raised about QA processes in place at its manufacturing facility.
Glaukos Pharmaceutical, an ophthalmic medical technology and pharmaceutical company, and D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company, have announced an agreement.
SurModics has completed the three year Phase I trial of I-vation TA (triamcinolone acetonide), which uses a novel drug delivery system capable of sustained ocular release of a therapeutic.
The pharmaceutical industry is doing little to help people with
impaired or partial sight get information from drug labels,
according to a new study which found a font change could alleviate
the issue.